Staphylococcus Aureus Testing Market

Staphylococcus Aureus Testing Market Outlook

The Staphylococcus aureus testing market is likely to cross the estimated market value of USD 6.9 billion by 2033 while it thrives in the global market at a lower CAGR of 5.3% (2023 to 2033). The market holds a revenue of USD 4.1 billion in 2023.

The market survey states that the rising number of infections is caused by Staphylococcus aureus. These infections include skin, bacteremia, soft tissue, and infective endocarditis. Furthermore, advanced technology is integrating with diagnostic procedures for staphylococcus aureus as it grows rapidly. The applications of staphylococcus aureus testing in cases of abscesses, furuncles, and cellulitis are rising with the growing awareness around skin care.

The Staphylococcus aureus market outlook shows that the market has been growing steadily since the last forecast cycle. This growth is attributed to the high risks of infected blood fluids and contaminated hands. The increasing sales of staphylococcus aureus testing systems are attributed to the growing geriatric population and skin health awareness. Staphylococcus aureus has long been recognized as an important bacteria that cause different human diseases.

Abscess infections include pocket infections formed around the site of injury that are pus-filled and pocket infections formed around the site of injury that is pus-filled in nature. Cellulitis involves an infection of the underlying layers of the skin. It happens due to some scrape or cut through the skin. The long types of infections are followed by their diagnosis of them. Hence the demand for staphylococcus aureus testing.

Attributes	Details
Market CAGR (2023 to 2033)	5.3%
Market Valuation (2023)	USD 4.1 billion
Market Valuation (2033)	USD 6.9 billion

What are the Major Drivers and Restraints of the Global Market?

The growing incidence of staph infections is the major factor driving the growth of the global market. An inappropriate sanitary environment is the major cause of the spread of Staph infections. Staphylococcus aureus screening is the mandatory screening test before taking insulin, and growing awareness of bacterial infection across the globe is expected to push the sales of staphylococcus aureus testing systems.

Advanced rapid diagnostic tests availability also boosts the market's growth over the forecast period. However, inadequate reimbursement in developing the region and limited access to regular healthcare may be the restraints for the global market.

Growth Prospects:

Test-based Developments

• Both rapid and reliable tests gained traction in the last forecast cycle with the new advanced technology like big data integrating with the test documentation, providing info like patient's history and nature of infection for better treatment.
• New RAPIDEC staph kits are used to detect the staphylococcus aureus bacteria that detect directly through the vital blood culture system.
• Some Staphylococcus aureus strains can produce staphylococcal enterotoxins (SEs), the causative agents of staphylococcal food poisoning. NCBI has been introduced to detect these agents through a specific

Market-based Developments

• Big companies like Hygiene are launching rapid BAX System PCR Assays for detecting staphylococcus aureus to help the end user healthcare systems.
• As companies focus more on accuracy and less on the packaging and marketing of these testing kits. Bio-Rad labs have introduced its TC-139 testing kits that have to shorten the result time.

Sales Analysis of Staphylococcus Aureus Testing Market from 2018 to 2022 Vs Market Outlook for 2023 to 2033

The global market is projected to rise at an impressive CAGR of 5.3% between 2023 and 2033, compared to a 6.7% CAGR registered from 2018 to 2022. The market secured a valuation of USD 2.8 billion in 2018 and USD 3.9 billion in 2022.

Regional Analysis

What is the North America Growth Outlook for the Market?

Emerging trends in the market state that the North American market holds a significant market share, with 48.7% of the global market share. The growth factors that work for the development of the market are increasing contaminated infections, pollution and proliferated bacteria counts in food products that lead to higher sensitivity levels in Americans.

Oxford Academic states that the high burden of staphylococcus aureus among Native American individuals on the White Mountain Apache tribal lands is rising. It increases demand for staphylococcus aureus testing in the region.

How is the European Market Shaping?

With a global market share of 33.4%, the European market is growing at an impressive CAGR as the covid-19 has slowed down bacteria contamination.

The new advanced technology, with its highly accurate results, is taking the lead in the market in the region. However, the logistics ban and lockdown have slowed down the market’s pace as there was limited human density in public spaces. Furthermore, the market recovers as the awareness of bacteria-based infections and diseases rises with the changing climate.

How are Startups Structuring the Global Market?

Staphylococcus aureus testing startup survey at future marketing insights explains that just like other healthcare/medical/diagnostics market spaces, this market is full of startup ideas that show interest in the rapidly changing diagnosis industry.

The new companies are investing more in the core workings of the staphylococcus aureus testing systems that reduce the testing time and increase the accuracy of the results. As the climate changes and new bacteria-based diseases expand, the different variants of Abscess and Cellulitis infections.

How Key Players are Contributing to the Global Market?

Key players now add more value to the accuracy of tests and logistics of these Staphylococcus aureus testing systems generally found in diagnostic centers. The new and advanced technology used detects all types of infections. The new startup is shaping the competitive landscape into more edgy and friendly.

Recent mergers and product launches

Abbott Laboratories has introduced its Abbott MS-2 system for staphylococcus aureus testing, which is methicillin-resistant. The agreement between Abbott MS-2 and standard disk diffusion methods procedure has been 94% greater than the antibiotics tested.

Thermofisher Scientific has introduced the Staphylococcal Enterotoxin Reversed Passive Latex Agglutination Kit (SET-RPLA) that detects enterotoxins A, B, C and D in food samples or culture filtrates. Reversed passive latex agglutination (RPLA) enables soluble antigens, such as bacterial toxins, to be detected in an agglutination assay.

Key players

• Abbott Laboratories Inc
• Siemens Healthcare GmbH
• Bio Rad Laboratories Inc
• Thermo Fisher Scientific Inc
• Roche Diagnostics (H. Hoffman-La Roche Ltd.)
• STD Rapid Test Kits

Scope of Report

Attributes	Details
Forecast Period	2023 to 2033
Historical Data Available for	2018 to 2022
Market Analysis	USD billion for Value
Key Countries Covered	United States, United Kingdom, Japan, India, China, Australia, Germany
Key Segments Covered	Product, Application, End User, Region
Key Companies Profiled	Abbott Laboratories Inc; Siemens Healthcare GmbH; Bio Rad Laboratories Inc; Thermo Fisher Scientific Inc; Roche Diagnostics (H. Hoffman-La Roche Ltd.); STD Rapid Test Kits
Report Coverage	Market Forecast, Company Share Analysis, Competition Intelligence, DROT Analysis, Market Dynamics and Challenges, and Strategic Growth Initiatives
Customization & Pricing	Available upon Request

Staphylococcus Aureus Testing Market by Category

By Test Type:

• Coagulase Test
• Ancillary Tests
• Agar-Based Tests
• Nucleic Acid Amplification Tests

By Application:

• Pharmaceutical
• Clinical
• Food Testing
• Other

By End User:

• Hospitals
• Diagnostic Clinics
• Food Testing laboratories
• Others

By Region:

• North America
• Latin America
• Europe
• Asia Pacific
• Middle East and Africa

Frequently Asked Questions

What is the CAGR from 2023 to 2033?

The CAGR of this market is 5.3% through 2033

Which Region holds high Lucrativeness?

North America is projected to emerge as a lucrative market.

What Limits the Growth Potential of the Market?

Limited access to regular healthcare limits the market growth.

What is North America's expected share in 2023?

North America is likely to generate 48.7% revenue in 2023

What drives sales in this market?

Growing awareness of bacterial infection is expected to drive sales.